Clinical Implication of HIF-PH Inhibitor in Patients with Heart Failure, Chronic Kidney Disease, and Renal Anemia
Yuki Hida, Teruhiko Imamura, Koichiro Kinugawa, Radica Alicic, Walter Grosso Marra · 2024
Read Clinical Implication of HIF-PH Inhibitor in Patients with Heart Failure, Chronic Kidney Disease, and Renal Anemia by Yuki Hida, Teruhiko Imamura, Koichiro Kinugawa, Radica Alicic, Walter Grosso Marra (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11676692.txt.
Description
Yuki Hida, Teruhiko Imamura, Koichiro Kinugawa, and two colleagues test anemia drugs in failing hearts in this two thousand twenty-four retrospective study. HIF-PH inhibitors treat kidney-related anemia by mimicking hypoxia signaling, but their effect when heart failure coexists was uncertain. The authors followed sixty-nine patients with both heart failure and renal anemia, comparing the six months before treatment with six months on the drug. The patients were elderly, median age eighty-two, with severely reduced kidney function.
Before treatment, hemoglobin had fallen from ten point five to nine point two grams per deciliter. On the inhibitor it rebounded to ten point nine. The rise came with lower BNP, a heart failure marker, improved kidney function, and reduced inflammation, all statistically significant. The authors conclude HIF-PH inhibitors corrected renal anemia in this difficult group while easing, not worsening, heart failure severity.
Catalog record
| CREATOR | Yuki Hida, Teruhiko Imamura, Koichiro Kinugawa, Radica Alicic, Walter Grosso Marra |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |